Oxaliplatin: an effective treatment in colorectal cancer

Authors

  • Yuxuan Yang

DOI:

https://doi.org/10.61173/y5hedh61

Keywords:

Oxaliplatin (trans-/-diamino cyclohexane oxalatoplatinum; L-OHP), HMGB-1, colorectal cancer, HCT116, ICD

Abstract

Colorectal cancer is one of the most common malignancies around the world. Oxaliplatin is a new platinum compound
with promising activity in colorectal cancer treatment. Based on the analysis of preclinical data. Because Oxaliplatin
can lead to ICD (Immunogenic cell death), the study aims to figure out whether increasing concentrations and treatment
durations with Oxaliplatin can kill colorectal cancer cells to test whether Oxaliplatin has a significant effect on colorectal
cancer treatment. Using the human colorectal cancer cell line HCT116, the cancer cells will be treated with Oxaliplatin
and PBS (negative control) at concentrations 1 mM, 10 mM, or 100 mM in a dose-dependent and duration-dependent
manner (1,3,6,12,24 hours ). Measure killing in vitro with MTT assay and measure tumor size in vivo. Also, measure
HMGB-1 released by western blot and CRT by FACS. The positive control is cisplatin, and the negative is PBS/DMSO
for in vitro and saline solution for in vivo. The study’s findings will supply insight into the latent capacity of Oxaliplatin
as a treatment for colorectal cancer in the future.

References

[1] Fang-fang Qi, Yunyao Yang, Haowen Zhang, Hongping Chen; Long non-coding RNAs: Key regulators in oxaliplatin resistance of colorectal cancer, Biomedicine & Pharmacotherapy, Volume 128,2020,110329, ISSN 0753-3322.

[2] Polastro L, El Hachem G, Hendlisz A. Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer. Curr Opin Oncol. (2018) 30:269–75. doi: 10.1097/CCO.00000000 00000455

[3] Chan GHJ, Chee CE. Making sense of adjuvant chemotherapy in colorectal cancer. J Gastrointest Oncol. (2019) 10:1183–92. doi: 10.21037/jgo.2019.06.03

[4] Colorectal Cancer Collaborative G. Palliative chemotherapy for advanced colorectal cancer: systematic review and metaanalysis. BMJ321(7260), 531–535 (2000)

[5] H Bleiberg; Oxaliplatin (L-OHP): a new reality in colorectal cancer, British Journal of Cancer volume, 01 January 1998, pages1–3.

[6] Yu X, Li Z, Yu J, Chan MT, Wu WK. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif. (2015) 48:503–10. doi: 10.1111/cpr.12202

[7] Moradi-Marjaneh R, Khazaei M, Seifi S, Hassanian SM, Ferns GA, Avan A. Pharmacogenetics of anticancer drug sensitivity and toxicity in colorectal cancer. Curr Pharm Des. (2018) 24:2710–8. doi:10.2174/1381612824666180727144535

[8] Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J ClinOncol. 2008;26:2013–2019.

[9] Chu E, Schulman KL, McKenna EF, Jr, et al. Patients with locallyadvanced and metastatic colorectal cancer treated with capecita-bine versus 5-fluorouracil as monotherapy or combination ther-apy with oxaliplatin: a cost comparison. Clin Colorectal Cancer.2010;9:229–237.

[10] Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposuredictates the immunogenicity of cancer cell death. Nat Med.. 2007;13:54–61. Epub 2006/12/26.

[11] Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death incancer therapy. Annu Rev Immunol.. 2013;31:51–72. Epub 2012/11/20.

[12] Showalter A, Limaye A, Oyer JL, et al. Cytokines in immunogeniccell death: applications for cancer immunotherapy. Cytokine.2017;97:123–132. Epub 2017/06/27.

[13] Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death ofcolon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482–491. Dean&Francis

[14] Qian Xiao-Lan, Zhou Fang, Xu Song, Jiang Jian, Chen Zhi- Peng, Wang Shao-Kai, Zuo Yun, Ni Che.MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer. Frontiers in Oncology. VOLUME=11-2021. DOI=10.3389/ fonc.2021.638537. ISSN=2234-943X

[15] Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.343(13), 905–914 (2000).

[16] de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18(16), 2938–2947 (2000).

Downloads

Published

2023-06-01

Issue

Vol. 1 No. 1 (2023): Volume 1, Issue 1

Section

Articles

License

Copyright (c) 2023 by the authors.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.